Can ICER Put a Price on Asthma Control?
October 17, 2018
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis omits key details.
Categorized in: Analysis
Recent Blog Posts
Why Don’t Insurers Take Obesity Seriously?
June 30, 2022
Feds Poised to Take a Hard Look at Pharmacy Benefit Managers
June 28, 2022
Federal Court Upholds West Virginia Law that Reigns in “Bad Drug” Ads
June 24, 2022